Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections

References

• AiresJRKohlerTNikaidoHInvolvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosidesAntimicrob Agents Chemother1999432624810543738
   PubMed Web of Science ®Google Scholar
• AlloMDBennionRSKathirKTicarcillin/clavulanate versus imipenem/cilistatin for the treatment of infections associated with gangrenous and perforated appendicitisAm Surg199965991049926739
   PubMed Web of Science ®Google Scholar
• AngerasMHDarleNHamnstromKA comparison of imipenem/cilastatin with the combination of cefuroxime and metronidazole in the treatment of intra-abdominal infectionsScand J Infect Dis199628513188953684
   PubMed Web of Science ®Google Scholar
• BabinchakTEllis-GrosseEDartoisNThe efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial dataClin Infect Dis200541Suppl 5S3546716080073
   PubMed Web of Science ®Google Scholar
• BainesSDSaxtonKFreemanJTigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut modelJ Antimicrob Chemother2006581062517030519
   PubMed Web of Science ®Google Scholar
• BariePSVogelSBDellingerEPA randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-abdominal Infection Study GroupArch Surg199713212943029403533
   PubMed Web of Science ®Google Scholar
• BasoliAMeliEZMazzocchiPImipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trialScand J Infect Dis19972950389435041
   PubMed Web of Science ®Google Scholar
• BergeronJAmmiratiMDanleyDGlycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protectionAntimicrob Agents Chemother199640222688878615
   PubMed Web of Science ®Google Scholar
• BerneTVYellinAEApplemanMDMeropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitisJ Am Coll Surg199618240378620275
   PubMed Web of Science ®Google Scholar
• BochicchioGVBaqueroFHsuehPRIn vitro susceptibilities of Escherichia coli isolated from patients with intra-abdominal infections worldwide in 2002-2004: results from SMART (Study for Monitoring Antimicrobial Resistance Trends)Surg Infect (Larchmt)200675374517233571
   PubMedGoogle Scholar
• BogaertsPNaasTWyboIOutbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in BelgiumJ Clin Microbiol20064441899216957031
   PubMed Web of Science ®Google Scholar
• BogdanovichTEselDKellyLMAntistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agentsAntimicrob Agents Chemother20054933253316048943
   PubMed Web of Science ®Google Scholar
• BouchillonSKHobanDJJohnsonBMIn vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004)Diagn Microbiol Infect Dis2005a52173916105561
   PubMed Web of Science ®Google Scholar
• BouchillonSKHobanDJJohnsonBMIn vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002Diagn Microbiol Infect Dis2005b51291515808321
   PubMed Web of Science ®Google Scholar
• BradfordPAWeaver-SandsDTPetersenPJIn vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infectionsClin Infect Dis200541Suppl 5S3153216080070
   PubMed Web of Science ®Google Scholar
• BreedtJTerasJGardovskisJSafety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonamAntimicrob Agents Chemother20054946586616251309
   PubMed Web of Science ®Google Scholar
• BrismarBMalmborgASTunevallGMeropenem versus imipenem/cilastatin in the treatment of intra-abdominal infectionsJ Antimicrob Chemother199535139487768761
   PubMed Web of Science ®Google Scholar
• BrismarBMalmborgASTunevallGPiperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infectionsAntimicrob Agents Chemother1992362766731336347
   PubMed Web of Science ®Google Scholar
• [CDCP] Centers for Disease Control and Prevention, National Health Center for StatisticsVital and Health Statistics: Detailed Diagnoses and Procedures1997Hyattsville, MDU.S. Department of Health and Human Services National Hospital Discharge Survey, 1994. Vol. 127
   Google Scholar
• [CDER] Centers for Drug Evaluation and ResearchUncomplicated and complicated skin and skin structure infections – Developing antimicrobial drugs for treatement. Guidance for Industry (online)1998 Accessed 5 May 2007. URL: http://www.fda.gov/cder/guidance/2566dft.pdf
   Google Scholar
• CercenadoEMarinMSanchez-MartinezMIn Vitro Activities of Tigecycline and Eight Other Antimicrobials against Different Nocardia Species Identified by Molecular MethodsAntimicrob Agents Chemother2007511102417194827
   PubMed Web of Science ®Google Scholar
• ChengNCHsuehPRLiuYCIn vitro activities of tigecycline, ertapenem, isepamicin, and other antimicrobial agents against clinically isolated organisms in TaiwanMicrob Drug Resist2005113304116359192
   PubMed Web of Science ®Google Scholar
• ChopraIHawkeyPMHintonMTetracyclines, molecular and clinical aspectsJ Antimicrob Chemother199229245771592696
   PubMed Web of Science ®Google Scholar
• ChopraIRobertsMTetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistanceMicrobiol Mol Biol Rev2001652326011381101
   PubMed Web of Science ®Google Scholar
• ChristouNVTurgeonPWassefRManagement of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Intra-abdominal Infection Study GroupArch Surg199613111932018911260
   PubMedGoogle Scholar
• [CLSI] Clinical and Laboratory Standards Institute [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically2003a6Wayne, PA
   Google Scholar
• [CLSI] Clinical and Laboratory Standards Institute [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Performance standards for antimicrobial disk diffusion susceptibility tests2003b8Wayne, PA
   Google Scholar
• [CLSI] Clinical and Laboratory Standards Institute [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Methods for antimicrobial susceptibility testing of anaerobic bacteria20046Wayne, PA
   Google Scholar
• [CLSI] Clinical and Laboratory Standards Institute [formerly National Committee for Clinical Laboratory Standards (NCCLS)]Performance standards for antimicrobial susceptibility testing – 15th informational supplement2005Wayne, PA
   Google Scholar
• CohnSMLipsettPABuchmanTGComparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infectionsAnn Surg20002322546210903605
   PubMed Web of Science ®Google Scholar
• ColardynFFaulknerKLIntravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study GroupJ Antimicrob Chemother199638523378889726
   PubMed Web of Science ®Google Scholar
• CondonREWalkerAPSirinekKRMeropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trialClin Infect Dis199521544508527541
   PubMed Web of Science ®Google Scholar
• ConteJEJrGoldenJAKellyMGSteady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecyclineInt J Antimicrob Agents200525523915885987
   PubMed Web of Science ®Google Scholar
• CuetoJD’AllemagneBVazquez-FriasJAMorbidity of laparoscopic surgery for complicated appendicitis: an international studySurg Endosc2006207172016544077
   PubMed Web of Science ®Google Scholar
• DeanCRVisalliMAProjanSJEfflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1Antimicrob Agents Chemother200347972812604529
   PubMed Web of Science ®Google Scholar
• DinubileMJLipskyBAComplicated infections of skin and skin structures: When the infection is more than skin deepJ Antimicrob Chemother200453Suppl S2ii375015150182
   PubMedGoogle Scholar
• DoernGVJonesRNPfallerMABacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America)Diagn Microbiol Infect Dis199934657210342110
   PubMed Web of Science ®Google Scholar
• DonahuePESmithDLYellinAETrovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multi-center comparison with imipenem/cilastatin. Trovafloxacin Surgical GroupAm J Surg199817653S61S9935258
   PubMed Web of Science ®Google Scholar
• DoughertySHSirinekKRSchauerPRTicarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patientsAm Surg1995612973037893090
   PubMed Web of Science ®Google Scholar
• EklundAENordCEA randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study GroupJ Antimicrob Chemother199331Suppl A79858383657
   PubMed Web of Science ®Google Scholar
• Ellis-GrosseEJBabinchakTDartoisNThe efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonamClin Infect Dis200541Suppl 5S3415316080072
   PubMed Web of Science ®Google Scholar
• Ellis-GrosseEBradfordPALohETigecycline in patients with extended-spectrum beta lactamases (ESBLs) - producing bacteria: experience from Phase III clinical trials200543rd Infectious Diseases Society of AmericaOctober 6–9San Francisco, CA meeting abstract
   Google Scholar
• FabianTCFileTMEmbilJMMeropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative studySurg Infect (Larchmt)200562698216201937
   PubMedGoogle Scholar
• FassRJFreimerEHMcCloskeyRVTreatment of skin and soft tissue infections with imipenem/cilastatinAm J Med198578110123890532
   PubMed Web of Science ®Google Scholar
• FominPBeuranMGradauskasAealTigecycline is efficacious in the treatment of complicated intra-abdominal infectionsInt J Surg20053354717462257
   PubMedGoogle Scholar
• FritscheTRSaderHSStilwellMGPotency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000–2004)Diagn Microbiol Infect Dis20055219520116105564
   PubMed Web of Science ®Google Scholar
• FritscheTRStrabalaPASaderHSActivity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolatesDiagn Microbiol Infect Dis2005522091316105566
   PubMed Web of Science ®Google Scholar
• GalesACJonesRNAndradeSSIn vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin AmericaBraz J Infect Dis200593485616410885
   PubMedGoogle Scholar
• GarrisonMWNuemillerJJIn vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococciInt J Antimicrob Agents200729191617174074
   PubMed Web of Science ®Google Scholar
• GeroulanosSJMeropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study GroupJ Antimicrob Chemother199536Suppl A1912058543495
   PubMed Web of Science ®Google Scholar
• GiordanoPSongJPertelPSequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionInt J Antimicrob Agents2005263576516229991
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVComparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agentsAntimicrob Agents Chemother20065035071316940056
   PubMed Web of Science ®Google Scholar
• GotfriedMHRodvoldKACwikMAn open-label clinical evaluation of tigecycline concentrations in selected tissues and fluidsClin Pharmacol Ther20057798
   Web of Science ®Google Scholar
• GrahamDRLucastiCMalafaiaOErtapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter studyClin Infect Dis2002341460812015692
   PubMed Web of Science ®Google Scholar
• GrahamDRTalanDANicholsRLOnce-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trialClin Infect Dis200235381912145720
   PubMed Web of Science ®Google Scholar
• GraysonMLMcDonaldMGibsonKOnce-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adultsClin Infect Dis2002341440812015689
   PubMed Web of Science ®Google Scholar
• HobanDJBouchillonSKJohnsonBMIn vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)Diagn Microbiol Infect Dis2005522152716105567
   PubMed Web of Science ®Google Scholar
• HoffmannMDeMaioWJordanRAMetabolic disposition (14C) tigecycline in human volunteers following intravenous infusion2004American Association of Pharmaceutical Scientists (AAPS) Annual MeetingNovember 7–11Baltimore, MD meeting abstract
   Google Scholar
• HuizingaWKWarrenBLBakerLWAntibiotic monotherapy with meropenem in the surgical management of intra-abdominal infectionsJ Antimicrob Chemother199536Suppl A179898543493
   PubMed Web of Science ®Google Scholar
• JaccardCTroilletNHarbarthSProspective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitisAntimicrob Agents Chemother1998422966729797234
   PubMed Web of Science ®Google Scholar
• KirklandKBBriggsJPTrivetteSLThe impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costsInfect Control Hosp Epidemiol1999207253010580621
   PubMed Web of Science ®Google Scholar
• KohlerTMichea-HamzehpourMHenzeUCharacterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosaMol Microbiol199723345549044268
   PubMed Web of Science ®Google Scholar
• LeeSYKutiJLNicolauDPAntimicrobial management of complicated skin and skin structure infections in the era of emerging resistanceSurg Infect2005628395
   PubMedGoogle Scholar
• LiXZNikaidoHPooleKRole of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosaAntimicrob Agents Chemother1995391948538540696
   PubMed Web of Science ®Google Scholar
• LipskyBAStoutenburghUDaptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infectionsJ Antimicrob Chemother200555240515659542
   PubMed Web of Science ®Google Scholar
• MeagherAKAmbrosePGGraselaTHPharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agentDiagn Microbiol Infect Dis2005521657116105560
   PubMed Web of Science ®Google Scholar
• MeagherAKPassarellJACirincioneBBExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infectionsAntimicrob Agents Chemother20075119394517353238
   PubMed Web of Science ®Google Scholar
• MineTMoritaYKataokaAExpression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosaAntimicrob Agents Chemother199943415179925549
   PubMed Web of Science ®Google Scholar
• MoetGJJonesRNBiedenbachDJContemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998–2004)Diagn Microbiol Infect Dis20075771317059876
   PubMed Web of Science ®Google Scholar
• MongeJVde Los TerrerosLSolerLDiaz-Agero PerezCExcess length of stay attributable to surgical site infection following hip replacement: a nested case-control studyInfect Control Hosp Epidemiol200627129930317152026
   PubMed Web of Science ®Google Scholar
• MuralidharanGFruncilloRJMicalizziMEffects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjectsAntimicrob Agents Chemother2005491656915793165
   PubMed Web of Science ®Google Scholar
• MuralidharanGMicalizziMSpethJPharmacokinetics of tigecycline after single and multiple doses in healthy subjectsAntimicrob Agents Chemother200549220915616299
   PubMed Web of Science ®Google Scholar
• NicholsRLOptimal treatment of complicated skin and skin structure infectionsJ Antimicrob Chemother199944Suppl A192310511393
   PubMed Web of Science ®Google Scholar
• NicholsRLFlormanSClinical presentations of soft-tissue infections and surgical site infectionsClin Infect Dis200133Suppl 2S849311486304
   PubMed Web of Science ®Google Scholar
• NicholsRLGrahamDRBarriereSLTreatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection GroupJ Antimicrob Chemother1999442637310473234
   PubMed Web of Science ®Google Scholar
• OhlinBCederbergAForssellHPiperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infectionsEur J Surg19991658758410533765
   PubMedGoogle Scholar
• OlivaMERekhaAYellinAA multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]BMC Infect Dis200558816236177
   PubMed Web of Science ®Google Scholar
• OlsonMWRuzinAFeyfantEFunctional, biophysical, and structural bases for antibacterial activity of tigecyclineAntimicrob Agents Chemother20065021566616723578
   PubMed Web of Science ®Google Scholar
• PelegAYPotoskiBAReaRAcinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary reportJ Antimicrob Chemother2007591283117082201
   PubMed Web of Science ®Google Scholar
• PetersenPJBradfordPAWeissWJIn vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediat Staphylococcus aureus and other resistant gram-positive pathogensAntimicrob Agents Chemother200246259560112121938
   PubMed Web of Science ®Google Scholar
• PoenaruDDeSMChristouNVImipenem versus tobramycin – antianaerobe antibiotic therapy in intra-abdominal infectionsCan J Surg199033415222224663
   PubMed Web of Science ®Google Scholar
• PooleKGotohNTsujimotoHOverexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosaMol Microbiol199621713248878035
   PubMed Web of Science ®Google Scholar
• PostierRGGreenSLKleinSRResults of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patientsClin Ther2004267041415220014
   PubMed Web of Science ®Google Scholar
• ProjanSJPreclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agentPharmacotherapy200020219S2311001329
   PubMed Web of Science ®Google Scholar
• RaibleDZimmermanJJHarperDPharmacokinetics and Pharmacodynamics of Tigecycline and Warfarin Coadministered to Healthy Subjects200545th Interscience Conference on Antimicrobial Agents and ChemotherapyDecember 16–19Washington, DC meeting abstract
   Google Scholar
• RasmussenBAGluzmanYTallyFPInhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclinesAntimicrob Agents Chemother1994381658607526784
   PubMed Web of Science ®Google Scholar
• ReeseABurgessDIn vitro pharmacodynamics and post-antibiotic effcts (PAE) of tigecycline against gram-negative bacteria200545th Interscience Conference on Antimicrobial Agents and ChemotherapyDecember 16–19Washington, DC meeting abstract
   Google Scholar
• RellojPharmacokinetics, pharmacodynamics, safety and tolerability of tigecyclineJ Chemother200517Suppl 1122216285354
   PubMed Web of Science ®Google Scholar
• RennieRPJonesRNMutnickAHOccurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)Diagn Microbiol Infect Dis2003452879312730001
   PubMed Web of Science ®Google Scholar
• RiceLBChallenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosaClin Infect Dis200643Suppl 2S100516894511
   PubMed Web of Science ®Google Scholar
• Rodriguez-AvialIRodriguez-AvialCLopezOIn vitro activity of tigecycline (GAR-936) and other antimicrobials against tetracycline- and ciprofloxacin-resistant Campylobacter clinical isolatesInt J Antimicrob Agents200627303616540293
   PubMed Web of Science ®Google Scholar
• RodvoldKAGotfriedMHCwikMSerum, tissue and body fluid concentrations of tigecycline after a single 100 mg doseJ Antimicrob Chemother2006581221917012300
   PubMed Web of Science ®Google Scholar
• RodvoldKGotfriedMCwikMTigeycline (TGC) concentration (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects200545th Interscience Conference on Antimicrobial Agents and ChemotherapyDecember 16–19Washington, DC meeting abstract
   Google Scholar
• SacchidanandSPennRLEmbilJMEfficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trialInt J Infect Dis200592516116099700
   PubMed Web of Science ®Google Scholar
• SaderHSJonesRNStilwellMGTigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continentsDiagn Microbiol Infect Dis200552181616105562
   PubMed Web of Science ®Google Scholar
• SaundersSBaird-BellaireSJPatatAAPharmacokinetics of tigecycline (TGC) in patients with hepatic impairment2005European Association for Clinical Pharmacology and TherapeuticsJune 24–29Poznan, Poland meeting abstract
   Google Scholar
• ScheetzMHReddyPNicolauDPPeritoneal fluid penetration of tigecyclineAnn Pharmacother2006402064717047138
   PubMed Web of Science ®Google Scholar
• SnydmanDRJacobusNVMcDermottLANational Survey on the Susceptibility of B. fragilis Group: Report and Analysis of Trends for 1997–2004: A US SurveyAntimicrob Agents Chemother20075116495517283189
   PubMed Web of Science ®Google Scholar
• SolomkinJSMazuskiJEBaronEJGuidelines for the selection of anti-infective agents for complicated intra-abdominal infectionsClin Infect Dis200337997100514523762
   PubMed Web of Science ®Google Scholar
• SolomkinJSReinhartHHDellingerEPResults of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study GroupAnn Surg1996223303158604912
   PubMed Web of Science ®Google Scholar
• SolomkinJSWilsonSEChristouNVResults of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infectionsAnn Surg2001233798711141229
   PubMed Web of Science ®Google Scholar
• SolomkinJSYellinAERotsteinODErtapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: results of a double-blind, randomized comparative phase III trialAnn Surg20032372354512560782
   PubMed Web of Science ®Google Scholar
• SorlozanoAGutierrezJSalmeronAActivity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, SpainInt J Antimicrob Agents200628532617045785
   PubMed Web of Science ®Google Scholar
• SpeerBSShoemakerNBSalyersAABacterial resistance to tetracycline: mechanisms, transfer, and clinical significanceClin Microbiol Rev19925387991423217
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541137340616231249
   PubMed Web of Science ®Google Scholar
• StevensDLSmithLGBrussJBRandomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infectionsAntimicrob Agents Chemother20004434081311083648
   PubMed Web of Science ®Google Scholar
• SturkenboomMCGoettschWGPicelliGInappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costsBr J Clin Pharmacol2005604384316187977
   PubMed Web of Science ®Google Scholar
• SunHKOngCTUmerAPharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrationsAntimicrob Agents Chemother20054916293215793157
   PubMed Web of Science ®Google Scholar
• TacconeFSRodriguez-VillalobosHDeBDSuccessful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecyclineEur J Clin Microbiol Infect Dis2006252576016572310
   PubMed Web of Science ®Google Scholar
• TalanDASummanenPHFinegoldSMAmpicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuseClin Infect Dis2000314647110987706
   PubMed Web of Science ®Google Scholar
• TallyFTEllestadGATestaRTGlycylcyclines: a new generation of tetracyclinesJ Antimicrob Chemother199535449527628979
   PubMed Web of Science ®Google Scholar
• TanJSWishnowRMTalanDATreatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study GroupAntimicrob Agents Chemother199337158068215266
   PubMed Web of Science ®Google Scholar
• [EUCAST Steering Committee] The European Committee on Antimicrobial Susceptility Testing (EUCAST) Steering CommitteeEUCAST technical note on tigecyclineClin Microbiol Infect2006121147917063597
   PubMed Web of Science ®Google Scholar
• TombsNLTissue distribution of GAR-936, a broad spectrum antibiotic in male rats199939th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 26–29San Francisco, CA meeting abstract
   Google Scholar
• TownsendMLPoundMWDrewRHTigecycline: a new glycylcycline antimicrobialInt J Clin Pract20066016627217109673
   PubMed Web of Science ®Google Scholar
• TroySMMuralidharanGMicalizziMThe effects of renal disease on the pharmacokinetics of tigecycline (GAR-936)200343rd Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 14–17Chicago, IL meeting abstract
   Google Scholar
• van OgtropMLAndesDStamstadTJIn vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteriaAntimicrob Agents Chemother200044943910722495
   PubMed Web of Science ®Google Scholar
• Van WartSAOwenJSLudwigEAPopulation pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infectionsAntimicrob Agents Chemother2006503701716940069
   PubMed Web of Science ®Google Scholar
• VegasAAJodraVMGarciaMLNosocomial infection in surgery wards: a controlled study of increased duration of hospital stays and direct cost of hospitalizationEur J Epidemiol19939504108307135
   PubMed Web of Science ®Google Scholar
• WaitesKBDuffyLBDowzickyMJAntimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobialAntimicrob Agents Chemother20065034798417005838
   PubMed Web of Science ®Google Scholar
• WalkerAPNicholsRLWilsonRFEfficacy of a beta-lactamase inhibitor combination for serious intra-abdominal infectionsAnn Surg1993217115218439209
   PubMed Web of Science ®Google Scholar
• Westbrock-WadmanSShermanDRHickeyMJCharacterization of Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeabilityAntimicrob Agents Chemother19994329758310582892
   PubMed Web of Science ®Google Scholar
• Wyeth PharmaceuticalsData on File (CSR-44355)2007aPhiladelphia, PA
   Google Scholar
• Wyeth PharmaceuticalsTygacil (package insert)2007bPhiladelphia, PA
   Google Scholar
• ZhanelGGHomenuikKNicholKThe glycylcyclines: a comparative review with the tetracyclinesDrugs200464638814723559
   PubMed Web of Science ®Google Scholar
• ZimmermanJJHarperDMatschkeKTigecycline and digoxin co-administered to healthy men200444th Interscience Conference on Antimicrobial Agents and ChemotherapyOctober 30–November 2Washington, DC meeting abstract
   Google Scholar
• ZimmermanJJHarperDMMatschkeKAbsence of an interaction between tigecycline and digoxin in healthy menPharmacotherapy2007278354417542766
   PubMed Web of Science ®Google Scholar